{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-088580","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.984348+00:00","generated_at":"2026-06-12T01:31:37.947495+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cognition Therapeutics Q2 net loss $4.7M; positive SEQUEL topline for CT1812","bullets":["Net loss of $4.7M ($0.16/sh) vs $5.8M ($0.25/sh) in Q2 2022; R&D expense $8.5M.","Cash and equivalents $37.2M; NIA grants remaining $81.8M; cash runway through Q3 2024.","Positive topline results from Phase 2 SEQUEL qEEG study; full data expected Q4 2023.","540-patient Phase 2 START trial (early Alzheimer's) recruiting; MAGNIFY dry AMD dosing started.","Published SNAP study confirming sigma-2 receptor target engagement of CT1812."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-088580","json":"https://secwatch.observer/filing/0001104659-23-088580.json","markdown":"https://secwatch.observer/filing/0001104659-23-088580.md","text":"https://secwatch.observer/filing/0001104659-23-088580.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465923088580/0001104659-23-088580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465923088580/tm2322819d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:31:37.947495+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"91ff7c72d0844a563a98764d6ae683735c307f33","claim":"COGNITION THERAPEUTICS INC reported the second quarter ended June 30, 2023 results: net income net loss of $4.7 million or $(0.16) per basic and diluted share.","evidence_excerpt":"The Company reported a net loss of $4.7 million or $(0.16) per basic and diluted share for the second quarter ended June 30, 2023, compared to a net loss of $5.8 million or $(0.25) per basic and diluted share during the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465923088580/0001104659-23-088580-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"net loss of $4.7 million or $(0.16) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}